Johnson & Johnson has exercised its option to acquire Arkuda’s portfolio of lysosomal function enhancers in exchange for an upfront payment and opportunity for additional milestone payments. WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ — Arkuda Therapeutics, a biotechnology company…
